Pour vous offrir la meilleure navigation, le AB Science
a été développé avec la dernière technologie Flash-Player.

Notre système à détecté que vous ne disposez pas de ce plugin.
Pour le télécharger gratuitement cliquez-ici

AB Science is a biopharmaceutical company specializing in the research, development, and commercialization of novel targeted therapies named tyrosine kinase inhibitors. Our target diseases are cancers, inflammatory diseases, and central nervous system diseases, in both human and veterinary medicine. The most advanced compound in the development process is masitinib. In veterinary medicine, masitinib (animal medicine trade name Masivet® in Europe or Kinavet® in USA) was registered as a canine cancer therapy by the European Union in November 2008, following a centralized review procedure from the European MedicineAgency. In human medicine, masitinib completed phase 2 clinical studies in eight indications with positive results and three international phase 3 clinical studies have been initiated with this drug, including pancreatic cancer, gastrointestinal stromal tumor and mastocytosis (an orphan disease). AB Science has developed a substantial portfolio of compounds and has several lead candidates in preclinical development.

Le site internet de la société AB Science a été développé par l'Agence K2